Recombinant Subunit Vaccine Development Services for SARS-CoV-2
Creative Biolabs is a global, research-based biotechnology company dedicated to the discovery and development of novel viral vaccines. Our researchers are working to improve the design of vaccines and develop novel approaches that can reduce cost and increase accessibility.
For decades, Creative Biolabs has been committed to the development of novel vaccines. We offer a variety of vaccine design services for SARS-CoV-2, including the subunit vaccine development services. Subunit vaccines contain only the necessary antigens and not the other components that make up the microorganism, so the possibility of adverse reactions to the vaccine is very low.
Similar to other enveloped RNA viruses, SARS-CoV-2 has a trimeric spike (S) protein on its viral envelope. Since the trimeric S protein of SARS-CoV-2 is responsible for binding to the host cell surface receptor ACE2 and mediating subsequent viral entry, the trimeric S protein is a very attractive candidate for developing subunit vaccines. Creative Biolabs has an innovative vaccine development platform that allows the production of novel, covalently-trimerized fusion proteins. With our unique vaccine development platform, we provide comprehensive SARS-CoV-2 S protein subunit vaccine development services, including gene synthesis, vector construction, protein expression and purification, immunoassay, etc.
With more than 10 years of vaccine development experience, Creative Biolabs provides integrated clinical and laboratory vaccine expertise and development services to advance our clients’ vaccine programs. Our experts are pleased to help you with our advanced platforms and extensive experiences. If you have any questions about our services, please feel free to contact us.For Research Use Only. We do not provide direct services or products for patients.
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.